Long-term response to successful acute pharmacological treatment of psychotic depression
Background: Data about follow-up after acute pharmacological treatment of psychotic depression are scarce. Methods: A 4 month open follow-up was done, preferentially with same medication as during acute treatment, of patients (n=59) with DSM-IV-TR major depressive disorder with psychotic features, aged 18 to 65 years, who had completed as responders an acute doubleblind 7 week trial with imipramine, venlafaxine or venlafaxine plus quetiapine. Main outcome measures were Hamilton Rating Scale for Depression and Clinical Global Impression Scale. Results: Six patients dropped out during the 4 month follow-up. Almost all patients (86.4%; 51/59) remained responder while remission rate increased from 59.3% (35/59) to 86.8% (46/53), independent of treatment. Relapse rate was low (3.8%; 2/53). Tolerability was good. Weight increased with all treatments. Limitations: Limitations were the limited sample size and consequent limited statistical power. The treatment during follow-up was not double-blind. Conclusions: Continuation treatment with the same medication that was effective in the acute treatment trial, remained effective during the 4 month follow-up in many patients leading to further improvement, and was well tolerated.
|Keywords||Adult, Affective Disorders, Psychotic/*drug therapy, Antidepressive Agents/*therapeutic use, Antipsychotic Agents/*therapeutic use, Cyclohexanols/*therapeutic use, Depressive Disorder, Major/*drug therapy, Dibenzothiazepines/*therapeutic use, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Imipramine/*therapeutic use, Long-Term Care, Male, Middle Aged, Netherlands, Treatment Outcome|
|Persistent URL||dx.doi.org/10.1016/j.jad.2009.10.014, hdl.handle.net/1765/23111|
Wijkstra, J, Burger, H, van den Broek, W.W, Birkenhäger, T.K, Janzing, J.G.E, Boks, M.P.M, … Nolen, W.A. (2010). Long-term response to successful acute pharmacological treatment of psychotic depression. Journal of Affective Disorders, 123(1-3), 238–242. doi:10.1016/j.jad.2009.10.014